Jan 30 - Feb 1, 2024
The summit gathers leading drug developers and microbiome experts to discuss microbiome functionality, translation, clinical development, biomarker discovery, and manufacturing scale-up
The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica’s microbiome-based immuno-oncology drug, BMC128
Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings throughout the week, starting on Monday, January 8, and concluding on Thursday, January 11, 2024.
Biomica Ltd. has announced the opening of a second site at The Davidoff Cancer Center for its ongoing Phase
Biomica Ltd. has announced the opening of a second site at The Davidoff Cancer Center for its ongoing Phase
The pre-clinical work was performed in collaboration with the lab of Prof. Kara Gross Margolis, Associate Director for Clinical and Translational Research for the New York University Pain Research Center and an Associate Professor in the Department of Molecular Pathobiology in the NYU College of Dentistry and the Department of Pediatrics at NYU Grossman School of Medicine.